Predictive Oncology (NASDAQ:POAI) Shares Cross Below 200 Day Moving Average of $3.00

Predictive Oncology Inc. (NASDAQ:POAI)’s share price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.00 and traded as low as $1.35. Predictive Oncology shares last traded at $1.39, with a volume of 28,250 shares trading hands.

Predictive Oncology Price Performance

The stock has a 50-day simple moving average of $2.69 and a 200-day simple moving average of $3.00. The stock has a market cap of $5.64 million, a P/E ratio of -0.40 and a beta of 1.29.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. bought a new stake in shares of Predictive Oncology during the first quarter worth about $54,000. Virtu Financial LLC bought a new stake in shares of Predictive Oncology during the first quarter worth about $66,000. Renaissance Technologies LLC grew its holdings in shares of Predictive Oncology by 2,582.8% during the second quarter. Renaissance Technologies LLC now owns 405,100 shares of the medical instruments supplier’s stock worth $166,000 after purchasing an additional 390,000 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Predictive Oncology during the third quarter worth about $65,000. Finally, Raymond James & Associates bought a new stake in shares of Predictive Oncology during the third quarter worth about $378,000. Institutional investors own 9.04% of the company’s stock.

Predictive Oncology Company Profile

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.